| [1] |
Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage:a current perspective[J]. Biochem Pharmacol, 2020, 180: 114147.
|
| [2] |
Park J, Jeon SR, Kim JO, et al. Rebleeding rate and risk factors in nonsteroidal anti-inflammatory drug-induced enteropathy[J]. J Dig Dis, 2018, 19(5): 279-287.
|
| [3] |
Tai FWD, McAlindon ME. NSAIDs and the small bowel[J]. Curr Opin Gastroenterol, 2018, 34(3): 175-182.
|
| [4] |
Watanabe T, Fujiwara Y, Chan FKL. Current knowledge on non-steroidal anti-inflammatory drug-induced small-bowel damage: a comprehensive review[J]. J Gastroenterol, 2020, 55(5): 481-495.
|
| [5] |
Maseda D, Ricciotti E. NSAID-gut microbiota interactions[J]. Front Pharmacol, 2020, 11: 1153.
|
| [6] |
Nadatani Y, Watanabe T, Suda W, et al. Gastric acid inhibitor aggravates indomethacin-induced small intestinal injury via reducing Lactobacillus johnsonii[J]. Sci Rep, 2019, 9(1): 17490.
|
| [7] |
Su TT, Lai SC, Lee A, et al. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth[J]. J Gastroenterol, 2018, 53(1): 27-36.
|
| [8] |
Takashima S, Tanaka F, Kawaguchi Y, et al. Proton pump inhibitors enhance intestinal permeability via dysbiosis of gut microbiota under stressed conditions in mice[J]. Neurogastroenterol Motil, 2020, 32(7): e13841.
|
| [9] |
Takeuchi K, Amagase K. Roles of cyclooxygenase, prostaglandin E2 and EP receptors in mucosal protection and ulcer healing in the gastrointestinal tract[J]. Curr Pharm Des, 2018, 24(18): 2002-2011.
|
| [10] |
Bjarnason I, Scarpignato C, Holmgren E, et al. Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs[J]. Gastroenterology, 2018, 154(3): 500-514.
|
| [11] |
Shimada S, Tanigawa T, Watanabe T, et al. Involvement of gliadin, a component of wheat gluten, in increased intestinal permeability leading to non-steroidal anti-inflammatory drug-induced small-intestinal damage[J]. PLoS One, 2019, 14(2): e0211436.
|
| [12] |
Wang PP, Jia YF, Wu RR, et al. Human gut bacterial β-glucuronidase inhibition: an emerging approach to manage medication therapy[J]. Biochem Pharmacol, 2021, 190: 114566.
|
| [13] |
Hutka B, Lázár B, Tóth AS, et al. The nonsteroidal anti-inflammatory drug ketorolac alters the small intestinal microbiota and bile acids without inducing intestinal damage or delaying peristalsis in the rat[J]. Front Pharmacol, 2021, 12: 664177.
|
| [14] |
Wang XL, Tang Q, Hou HQ, et al. Gut microbiota in NSAID enteropathy: new insights from inside[J]. Front Cell Infect Microbiol, 2021, 11: 679396.
|
| [15] |
Lázár B, László SB, Hutka B, et al. A comprehensive time course and correlation analysis of indomethacin-induced inflammation, bile acid alterations and dysbiosis in the rat small intestine[J]. Biochem Pharmacol, 2021, 190: 114590.
|
| [16] |
Yoshikawa K, Kurihara C, Furuhashi H, et al. Psychological stress exacerbates NSAID-induced small bowel injury by inducing changes in intestinal microbiota and permeability via glucocorticoid receptor signaling[J]. J Gastroenterol, 2017, 52(1): 61-71.
|
| [17] |
Colucci R, Pellegrini C, Fornai M, et al. Pathophysiology of NSAID-associated intestinal lesions in the rat: luminal bacteria and mucosal inflammation as targets for prevention[J]. Front Pharmacol, 2018, 9: 1340.
|
| [18] |
Sugimura N, Otani K, Watanabe T, et al. High-fat diet-mediated dysbiosis exacerbates NSAID-induced small intestinal damage through the induction of interleukin-17A[J]. Sci Rep, 2019, 9(1): 16796.
|
| [19] |
Maseda D, Zackular JP, Trindade B, et al. Nonsteroidal anti-inflammatory drugs alter the microbiota and exacerbate Clostridium difficile colitis while dysregulating the inflammatory response[J]. mBio, 2019, 10(1): e02282-e02218.
|
| [20] |
Mu?oz-Miralles J, Trindade BC, Castro-Córdova P, et al. Indomethacin increases severity of Clostridium difficile infection in mouse model[J]. Future Microbiol, 2018, 13(11): 1271-1281.
|
| [21] |
Yoshihara T, Oikawa Y, Kato T, et al. The protective effect of Bifidobacterium bifidum G9-1 against mucus degradation by Akkermansia muciniphila following small intestine injury caused by a proton pump inhibitor and aspirin[J]. Gut Microbes, 2020, 11(5): 1385-1404.
|
| [22] |
Tsujimoto H, Hirata Y, Ueda Y, et al. Effect of a proton-pump inhibitor on intestinal microbiota in patients taking low-dose aspirin[J]. Eur J Clin Pharmacol, 2021, 77(11): 1639-1648.
|
| [23] |
Li K, Cheng X, Jin R, et al. The influence of different proton pump inhibitors and potassium-competitive acid blockers on indomethacin-induced small intestinal injury[J/OL]. J Gastroenterol Hepatol, (2022-08-08)[2022-09-19]. https: //onlinelibrary.wiley.com/doi/10.1111/jgh.15973
|
| [24] |
Taha AS, McCloskey C, McSkimming P, et al. Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(7): 469-476.
|
| [25] |
Kyaw MH, Otani K, Ching JYL, et al. Misoprostol heals small bowel ulcers in aspirin users with small bowel bleeding[J]. Gastroenterology, 2018, 155(4): 1090-1097.e1.
|
| [26] |
Teutsch B, Boros E, Váncsa S, et al. Mucoprotective drugs can prevent and treat nonsteroidal anti-inflammatory drug-induced small bowel enteropathy: a systematic review and meta-analysis of randomized controlled trials[J]. Therap Adv Gastroenterol, 2021, 14: 17562848211038772.
|
| [27] |
Tanigawa T, Watanabe T, Higashimori A, et al. Rebamipide ameliorates indomethacin-induced small intestinal damage and proton pump inhibitor-induced exacerbation of this damage by modulation of small intestinal microbiota[J]. PLoS One, 2021, 16(1): e0245995.
|
| [28] |
Xu N, Zhang CP, Jing LL, et al. Protective effect and mechanism of rebamipide on NSAIDs associated small bowel injury[J]. Int Immunopharmacol, 2021, 90: 107136.
|
| [29] |
Oh DJ, Lee DH, Choi YJ, et al. Tu1234 - the effect of rebamipide on nsaid-induced gastroenteropathy compared with lansoprazole: a multi-center, randomized, open labeled, pilot study[J]. Gastroenterology, 2018, 154(6): S-910.
|
| [30] |
Zhao J, Fan YH, Ye W, et al. The protective effect of teprenone on aspirin-related gastric mucosal injuries[J]. Gastroenterol Res Pract, 2019, 2019: 6532876.
|
| [31] |
Chitapanarux T, Lertprasertsuke N, Kongnak A. Teprenone for the prevention of low-dose aspirin-induced gastric mucosal injury in Helicobacter pylori-negative patients[J]. Scand J Gastroenterol, 2019, 54(10): 1199-1204.
|
| [32] |
Chao GQ, Wang ZJ, Yang CY, et al. Teprenone ameliorates diclofenac-induced small intestinal injury via inhibiting protease activated receptors 1 and 2 activity[J]. Biomarkers, 2021, 26(1): 38-44.
|
| [33] |
Ota K, Takeuchi T, Kojima Y, et al. Preventive effect of ecabet sodium on low-dose aspirin-induced small intestinal mucosal injury: a randomized, double-blind, pilot study[J]. BMC Gastroenterol, 2019, 19(1): 4.
|
| [34] |
Scarpignato C, Dolak W, Lanas A, et al. Rifaximin reduces the number and severity of intestinal lesions associated with use of nonsteroidal anti-inflammatory drugs in humans[J]. Gastroenterology, 2017, 152(5): 980-982.e3.
|
| [35] |
Xiao X, Nakatsu G, Jin Y, et al. Gut microbiota mediates protection against enteropathy induced by indomethacin[J]. Sci Rep, 2017, 7: 40317.
|
| [36] |
Zhang JH, Sun YM, Wang R, et al. Gut microbiota-mediated drug-drug interaction between amoxicillin and aspirin[J]. Sci Rep, 2019, 9(1): 16194.
|
| [37] |
Pan FW, Zhang LY, Li M, et al. Predominant gut Lactobacillus murinus strain mediates anti-inflammaging effects in calorie-restricted mice[J]. Microbiome, 2018, 6(1): 54.
|
| [38] |
Mortensen B, Murphy C, O''Grady J, et al. Bifidobacteriumbreve Bif195 protects against small-intestinal damage caused by acetylsalicylic acid in healthy volunteers[J]. Gastroenterology, 2019, 157(3): 637-646.e4.
|
| [39] |
Fornai M, Pellegrini C, Benvenuti L, et al. Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy[J]. Nutrition, 2020, 70: 110583.
|
| [40] |
Xu CL, Qiao L, Ma L, et al. Biogenic selenium nanoparticles synthesized by Lactobacillus casei ATCC 393 alleviate intestinal epithelial barrier dysfunction caused by oxidative stress via Nrf2 signaling-mediated mitochondrial pathway[J]. Int J Nanomedicine, 2019, 14: 4491-4502.
|
| [41] |
Monteros MJM, Galdeano CM, Balcells MF, et al. Probiotic lactobacilli as a promising strategy to ameliorate disorders associated with intestinal inflammation induced by a non-steroidal anti-inflammatory drug[J]. Sci Rep, 2021, 11(1): 571.
|
| [42] |
Suzuki T, Masui AY, Nakamura J, et al. Yogurt containing Lactobacillus gasseri mitigates aspirin-induced small bowel injuries: a prospective, randomized, double-blind, placebo-controlled trial[J]. Digestion, 2017, 95(1): 49-54.
|
| [43] |
Jia B, Chen JN, Tian ZL, et al. Traditional Chinese medicine composition for treating small intestine mucosa injury caused by non-steroidal anti-inflammatory drugs, and preparation method and preparation thereof:
CN113908212A[P]. 2022-01-11.
|
| [44] |
Chao GQ, Ye FX, Yuan Y, et al. Berberine ameliorates non-steroidal anti-inflammatory drugs-induced intestinal injury by the repair of enteric nervous system[J]. Fundam Clin Pharmacol, 2020, 34(2): 238-248.
|
| [45] |
Wang ZL, Xu G, Li ZY, et al. NLRP3 inflammasome pharmacological inhibitors in Glycyrrhiza for NLRP3-driven diseases treatment: extinguishing the fire of inflammation[J]. J Inflamm Res, 2022, 15: 409-422.
|
| [46] |
Nakamura S, Watanabe T, Tanigawa T, et al. Isoliquiritigenin ameliorates indomethacin-induced small intestinal damage by inhibiting NOD-like receptor family, pyrin domain-containing 3 inflammasome activation[J]. Pharmacology, 2018, 101(5/6): 236-245.
|
| [47] |
Guo C, Huang KK, Zeng JH, et al. Extract of Chaenomeles speciosa (sweet) nakai prevents intestinal mucosal injury induced by non-steroidal anti-inflammatory drugs (NSAIDs) in mice[J]. Mod Food Sci Technol (现代食品科技), 2019, 35(11): 45-51.
|
| [48] |
Li XM, He JY, Li S, et al. Protective effect and mechanism of total triterpenoids from Chaenomeles speciosa (Sweet) Nakai against small intestinal injury induced by indomethacin in rats[J]. Pharmacol Clin Chin Mater Med (中药药理与临床), 2018, 34(5): 55-60.
|
| [49] |
He HB, Li XM, Li XQ, et al. Clinical efficacy of muguasantie combined with rebamipide in the treatment of small bowel injury induced by nonsteroidal anti-inflammatory drugs[J]. Pharmacol Clin Chin Mater Med (中药药理与临床), 2018, 34(4): 172-176.
|
| [50] |
Singh DP, Borse SP, Rana RT, et al. Curcumin, a component of turmeric, efficiently prevents diclofenac sodium-induced gastroenteropathic damage in rats: a step towards translational medicine[J]. Food Chem Toxicol, 2017, 108: 43-52.
|
| [51] |
Cao ST, Wang CC, Yan JT, et al. Curcumin ameliorates oxidative stress-induced intestinal barrier injury and mitochondrial damage by promoting Parkin dependent mitophagy through AMPK-TFEB signal pathway[J]. Free Radic Biol Med, 2020, 147: 8-22.
|
| [52] |
Nagai KT, Ueno Y, Tanaka S, et al. Polysaccharides derived from Ganoderma lucidum fungus mycelia ameliorate indomethacin-induced small intestinal injury via induction of GM-CSF from macrophages[J]. Cell Immunol, 2017, 320: 20-28.
|
| [53] |
Wang MY, Zhao H, Wen X, et al. Citrus flavonoids and the intestinal barrier: interactions and effects[J]. Compr Rev Food Sci Food Saf, 2021, 20(1): 225-251.
|
| [54] |
Chen SS, Jiang JP, Chao GQ, et al. Pure total flavonoids from Citrus protect against nonsteroidal anti-inflammatory drug-induced small intestine injury by promoting autophagy in vivo and in vitro[J]. Front Pharmacol, 2021, 12: 622744.
|
| [55] |
Singh DP, Borse SP, Nivsarkar M. Overcoming the exacerbating effects of ranitidine on NSAID-induced small intestinal toxicity with quercetin: providing a complete GI solution[J]. Chem Biol Interact, 2017, 272: 53-64.
|
| [56] |
Shu R, Wang CY, Meng Q, et al. Resveratrol enhances the protective effects of JBP485 against indomethacin-induced rat intestinal damage in vivo and vitro through up-regulating oligopeptide transporter 1 (Pept1)[J]. Biomed Pharmacother, 2019, 111: 251-261.
|
| [57] |
Playford RJ, Garbowsky M, Marchbank T. Pasteurized chicken egg powder stimulates proliferation and migration of AGS, RIE1, and caco-2 cells and reduces NSAID-induced injury in mice and colitis in rats[J]. J Nutr, 2020, 150(6): 1434-1442.
|
| [58] |
Le Phan TH, Park SY, Jung HJ, et al. The role of processed Aloe vera gel in intestinal tight junction: an in vivo and in vitro study[J]. Int J Mol Sci, 2021, 22(12): 6515.
|
| [59] |
Zhang DD, Zhou XT, Liu LY, et al. Glucomannan from Aloe vera gel promotes intestinal stem cell-mediated epithelial regeneration via the Wnt/β-catenin pathway[J]. J Agric Food Chem, 2021, 69(36): 10581-10591.
|
| [60] |
Kim MW, Kang JH, Shin E, et al. Processed Aloe vera gel attenuates non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by enhancing mucin expression[J]. Food Funct, 2019, 10(9): 6088-6097.
|
| [61] |
Wallace JL, Nagy P, Feener TD, et al. A proof-of-concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide-releasing anti-inflammatory drug[J]. Br J Pharmacol, 2020, 177(4): 769-777.
|
| [62] |
G?owacka U, Magierowska K, Wójcik D, et al. Microbiome profile and molecular pathways alterations in gastrointestinal tract by hydrogen sulfide-releasing nonsteroidal anti-inflammatory drug (ATB-352): insight into possible safer polypharmacy[J]. Antioxid Redox Signal, 2022, 36(4/5/6): 189-210.
|
| [63] |
Jung ES, Jang HJ, Hong EM, et al. The protective effect of 5-aminosalicylic acid against non-steroidal anti-inflammatory drug-induced injury through free radical scavenging in small intestinal epithelial cells[J]. Medicina (Kaunas), 2020, 56(10): 515.
|
| [64] |
Han YM, Park JM, Her S, et al. Revaprazan prevented indomethacin-induced intestinal damages by enhancing tight junction related mechanisms[J]. Biochem Pharmacol, 2020, 182: 114290.
|
百度学术
下载:
